1269667-57-3

Usage

Uses

Used in Pharmaceutical Manufacturing:
4-Chlorothieno[3,2-d]pyrimidine is used as a building block for the development of therapeutic drugs, leveraging its biological activity to create effective medications.
Used in Medical Research:
4-Chlorothieno[3,2-d]pyri... is employed in various medicinal chemistry protocols, serving as an essential ingredient for the synthesis of new drug candidates and the study of their potential applications in treating diseases.
Used in Anticancer Applications:
Derivatives of 4-Chlorothieno[3,2-d]pyrimidine have been studied for their anti-cancer properties, as they can intercalate or bind to DNA, potentially inhibiting tumor growth and progression. This makes them promising candidates for the development of novel cancer therapies.

Upstream product

• 1318133-04-8 4-chlorothieno[3,2-d]pyrimidine-7-carbaldehyde 
• 1318133-02-6 (4-chlorothieno[3,2-d]pyrimidine-7-yl)methanol 
• 1318133-00-4 (4-chlorothieno[3,2-d]pyrimidine-7-yl)methyl acetate 
• 175137-21-0 4-chloro-7-methylthieno[3,2-d]pyrimidine 
• 175137-13-0 7-methyl-3,4-dihydrothieno[3,2-d]pyrimidin-4-one 
• 209286-57-7 7-(bromomethyl)-4-chlorothieno[3,2-d]pyrimidine 
• 85006-31-1 3-amino-4-methyl-2-thiophenecarboxylic acid methyl ester 
• 1246223-44-8 methyl 4-chlorothieno[3,2-d]pyrimidine-7-carboxylate 
• 1269667-38-0 methyl 4-hydroxythieno[3,2-d]pyrimidine-7-carboxylate 
• 31169-25-2 7-bromothieno[3,2-d]pyrimidine-4(3H)-one 
• 16234-10-9 3H-thieno[3,2-d]pyrimidin-4-one 

Downstream Products

• 1269666-21-8 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid [2-chloro-6-fluoro-3-(2-methylpropane-1-sulfonylamino)phenyl]amide 
• 1269667-60-8 4-chloro-N-(2,6-dichloro-3-(propylsulfonamido)phenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1269666-22-9 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid [2,6-dichloro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1269666-24-1 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid (3-benzenesulfonylamino-2,6-difluoro-phenyl)amide 
• 1269667-61-9 4-chloro-N-(6-chloro-2-fluoro-3-(3-fluoropropylsulfonamido)phenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1269666-26-3 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid [6-chloro-2-fluoro-3-(3-fluoro-propane-1-sulfonylamino)phenyl]amide 
• 1269666-82-1 4-methoxyaminothieno[3,2-d]pyrimidine-7-carboxylic acid [2,6-dichloro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1269666-83-2 4-cyclopropylaminothieno[3,2-d]pyrimidine-7-carboxylic acid [2,6-dichloro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1269667-24-4 thieno[3,2-d]pyrimidine-7-carboxylic acid [2,6-dichloro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1318133-08-2 N-(4-bromo-3,5-dimethoxyphenyl)-4-chlorothieno[3,2-d]pyrimidine-7-carboxamide 
• 1318133-05-9 4-chloro-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318133-07-1 4-amino-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318128-97-0 4-(cyclopropylamino)-N-(2,6-difluoro-3,5-dimethoxyphenyl)thieno[3,2-d]pyrimidine-7-carboxamide 
• 1318130-12-9 N-(4-bromo-2,6-dichloro-3,5-dimethoxyphenyl)-4-chlorothieno[3,2-d]pyrimidine-7-carboxamide 

Relevant academic research and scientific papers

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties

Recent clinical data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma. Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low solubility requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures. Through structure-based design, we discovered a new class of highly potent aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles. The hinge binding moiety possesses a basic center imparting high solubility at gastric pH, addressing the dissolution limitation observed with our previous series. In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogues 32 and 35 (G945), molecules with desirable physicochemical properties, emerged as lead compounds with strong efficacy in a B-RafV600E mutant mouse xenograft model. Synthesis, SAR, lead selection, and evaluation of key compounds in animal studies will be described.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or trea